PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study
研究概览
详细说明
Data collected through the study may be used to address a range of research questions and use cases and objectives, including but not limited to study
- Creation of a cohort of psoriasis subjects to describe the clinical and patient-reported outcomes (PRO) and changes at 2,4, and 16 weeks after initiation of the advanced therapy.
- Inform clinical decision making by subjects and treating providers. This will be enabled through the standardized data collection including validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), and the recording of medication utilization data.
- Describe subject characteristics (i.e. comorbidity, medication history, sociodemographic) at baseline.
- For subjects with a dermatologist-confirmed diagnosis of psoriatic arthritis at baseline, to describe the joint pain and patient wellness.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Psoriasis Rapid Response Study Team
- 电话号码:6178655932
- 邮箱:ppd_corepsoriasis@thermofisher.com
学习地点
-
-
Massachusetts
-
Waltham、Massachusetts、美国、02451
- 招聘中
- CorEvitas, LLC
-
接触:
- Cathy Cheney
- 电话号码:508-555-1212
- 邮箱:corevitasregistrytrials@corevitas.com
-
接触:
- 电话号码:508-555-1212
- 邮箱:corevitasregistrytrials@corevitas.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
The inclusion criteria for this study will be as follows:
- Patient is at least 18 years of age at the time of study enrollment
- Patient has a diagnosis of moderate to severe plaque psoriasis based on an Investigator Global Assessment (IGA, part of routine care) score of 3 or 4 at the time of Enrollment.
- Patient is initiating new Eligible Medication for the first time for the treatment of PSO.
- Patient is willing and able to provide informed consent to participate in this study.
- Patient is willing to be seen in-person by their treating dermatology provider at two (2), four (4), and sixteen (16) weeks following initiation of the advanced therapy.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in the study:
- Patient is participating in a blinded clinical trial.
- Patients that do not receive at least 1 dose of the advanced therapy within 14 days following the Enrollment/Baseline visit for the study.
- Patients cannot be concurrently enrolled in both the CorEvitas PSO Registry and the CorEvitas Psoriasis (PSO) Rapid Response Non-Interventional Study.
A. Patients currently enrolled in the CorEvitas PSO Registry are ineligible for participation in the CorEvitas Psoriasis (PSO) Rapid Response Non-Interventional Study.
B. Patients otherwise meeting eligibility criteria can be enrolled in the CorEvitas Psoriasis (PSO) Rapid Response Non-Interventional Study C. Following completion or at time of Exit from the CorEvitas Psoriasis (PSO) Rapid Response Non Interventional Study, patients will be eligible to enroll into the CorEvitas PSO Registry for long term follow up at the standard of care cadence supported by the registry. A separate Informed consent will be obtained.
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Creation of a cohort of psoriasis subjects
大体时间:Baseline (Day 0), Week 2, 4 and 16 weeks after initiation of advanced therapy
|
Creation of a cohort of psoriasis subjects to describe the changes at 2,4, and 16 weeks after initiation of the advanced therapy.
|
Baseline (Day 0), Week 2, 4 and 16 weeks after initiation of advanced therapy
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.